Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $26,130.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 390 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $26,130.00. Following the transaction, the insider directly owned 23,308 shares of the company’s stock, valued at $1,561,636. This represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, March 18th, Elizabeth Yeu Lin sold 379 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $68.71, for a total transaction of $26,041.09.
• On Tuesday, March 17th, Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $69.42, for a total transaction of $26,032.50.

Tarsus Pharmaceuticals Stock Down 2.2%

TARS traded down $1.49 during trading hours on Thursday, hitting $66.75. 461,600 shares of the company’s stock were exchanged, compared to its average volume of 672,393. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of -41.20 and a beta of 0.55. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The stock’s 50-day moving average is $69.36 and its two-hundred day moving average is $70.18. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The business had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. raised its stake in Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after buying an additional 172 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $368,000. Invesco Ltd. boosted its stake in shares of Tarsus Pharmaceuticals by 8.0% during the 4th quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock worth $82,892,000 after acquiring an additional 75,351 shares during the period. Mackenzie Financial Corp acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $202,000. Finally, XTX Topco Ltd increased its holdings in shares of Tarsus Pharmaceuticals by 270.3% during the 4th quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock worth $1,507,000 after acquiring an additional 13,438 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is “Moderate Buy” and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Mizuho started coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price target for the company. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $100.00 target price for the company. Finally, Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.83.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.